Finally, the JAK1/2 inhibitor ruxolitinib, which blocks the JAK kinase upstream from STATs, has been successfully used to ameliorate CMC and autoimmunity in several STAT1 GOF patients [22, 76]. This evidence concerns the gene JAK1 and Autoimmunity.